Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Colorectal Neoplasms

  Free Subscription


Articles published in Int J Cancer

Retrieve available abstracts of 130 articles:
HTML format



Single Articles


    September 2022
  1. WATTS K, Wills C, Madi A, Palles C, et al
    Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand-foot syndrome.
    Int J Cancer. 2022;151:957-966.
    PubMed     Abstract available


  2. SUN M, Bjorge T, Teleka S, Engeland A, et al
    Interaction of leisure-time physical activity with body mass index on the risk of obesity-related cancers: A pooled study.
    Int J Cancer. 2022;151:859-868.
    PubMed     Abstract available


    August 2022
  3. MARTINI G, Ciardiello D, Dallio M, Famiglietti V, et al
    Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab.
    Int J Cancer. 2022;151:473-480.
    PubMed     Abstract available


  4. HARLID S, Van Guelpen B, Qu C, Gylling B, et al
    Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases.
    Int J Cancer. 2022;151:348-360.
    PubMed     Abstract available


    July 2022
  5. VAN BLARIGAN EL, Ma C, Ou FS, Bainter TM, et al
    Dietary fat in relation to all-cause mortality and cancer progression and death among people with metastatic colorectal cancer: data from CALGB 80405 (Alliance)/SWOG 80405.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34230.
    PubMed     Abstract available


  6. XU X, Duan X, Wang S, Zhang Y, et al
    Special issue "The advance of solid tumor research in China": Discoidin domain receptor 2 promotes colorectal cancer metastasis by regulating epithelial mesenchymal transition via activating AKT signaling.
    Int J Cancer. 2022 Jul 29. doi: 10.1002/ijc.34227.
    PubMed     Abstract available


  7. DIAS CARVALHO P, Martins F, Mendonca S, Ribeiro A, et al
    Mutant KRAS modulates colorectal cancer cells invasive response to fibroblast-secreted factors through the HGF/C-MET axis.
    Int J Cancer. 2022 Jul 23. doi: 10.1002/ijc.34225.
    PubMed     Abstract available


  8. LIU T, Zhang Q, Song C, Siyin ST, et al
    C-reactive protein trajectories and the risk of all cancer types: A prospective cohort study.
    Int J Cancer. 2022;151:297-307.
    PubMed     Abstract available


  9. ROELANDT P, Droogne W, Voros G, Van Aelst L, et al
    Are heart transplant recipients more at risk for anal squamous carcinoma than other solid organ transplant recipients?
    Int J Cancer. 2022;151:156-157.
    PubMed    


  10. ACHILLI P, Magistro C, Abd El Aziz MA, Calini G, et al
    Modest agreement between magnetic resonance and pathological tumor regression after neoadjuvant therapy for rectal cancer in the real world.
    Int J Cancer. 2022;151:120-127.
    PubMed     Abstract available


  11. LI J, You L, Xu Z, Bai H, et al
    Healthy lifestyle and the risk of conventional adenomas and serrated polyps: Findings from a large colonoscopy screening population.
    Int J Cancer. 2022;151:67-76.
    PubMed     Abstract available


  12. SOLOMON A, Alteber Z, Bassan D, Sharbi-Yunger A, et al
    On the development of a neoantigen vaccine for the prevention of Lynch Syndrome.
    Int J Cancer. 2022;151:107-119.
    PubMed     Abstract available


    June 2022
  13. PING J, Yang Y, Wen W, Kweon SS, et al
    Developing and validating polygenic risk scores for colorectal cancer risk prediction in East Asians.
    Int J Cancer. 2022 Jun 29. doi: 10.1002/ijc.34194.
    PubMed     Abstract available


  14. FATEMI N, Tierling S, Es HA, Varkiani M, et al
    DNA Methylation Biomarkers in Colorectal Cancer: Clinical Applications for Precision Medicine.
    Int J Cancer. 2022 Jun 22. doi: 10.1002/ijc.34186.
    PubMed     Abstract available


  15. WATANABE J, Maeda H, Nagasaka T, Yokota M, et al
    Multicenter, single-arm, phase II study of the continuous use of panitumumab in combination with FOLFIRI after FOLFOX for RAS wild-type metastatic colorectal cancer - Exploratory sequential examination of acquired mutations in circulating cell-free DN
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34184.
    PubMed     Abstract available


  16. JIANG Z, Yang Z
    Comments on: Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation in vitro through interleukin-6-induced regulation of DNA damage.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34175.
    PubMed    


  17. ORANGE ST, Jordan AR, Odell A, Kavanagh O, et al
    Reply to "Comments on: Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation in vitro through interleukin-6-induced regulation of DNA damage".
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34177.
    PubMed    


  18. WANG L, Knudsen MD, Lo CH, Wang K, et al
    Adherence to a healthy lifestyle in relation to colorectal cancer incidence and all-cause mortality after endoscopic polypectomy: a prospective study in three U.S. cohorts.
    Int J Cancer. 2022 Jun 18. doi: 10.1002/ijc.34176.
    PubMed     Abstract available


  19. DESCHASAUX-TANGUY M, Barrubes Pinol L, Sellem L, Debras C, et al
    Dairy product consumption and risk of cancer: A short report from the NutriNet-Sante prospective cohort study.
    Int J Cancer. 2022;150:1978-1986.
    PubMed     Abstract available


  20. TORREGROSA C, Pernot S, Vaflard P, Perret A, et al
    FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): An AGEO multicenter study.
    Int J Cancer. 2022 Jun 15. doi: 10.1002/ijc.34166.
    PubMed     Abstract available


  21. RAIMONDI A, Randon G, Prisciandaro M, Pagani F, et al
    Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: overall and sex-specific outcomes in the Valentino trial.
    Int J Cancer. 2022 Jun 9. doi: 10.1002/ijc.34156.
    PubMed     Abstract available


  22. BAMBERG LV, Heigwer F, Wandmacher AM, Singh A, et al
    Targeting euchromatic histone lysine methyltransferases sensitizes colorectal cancer to histone deacetylase inhibitors.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34155.
    PubMed     Abstract available


  23. VAN ROOIJEN KL, Derksen JWG, Verkooijen HM, Vink GR, et al
    Translation of IDEA trial results into clinical practice: analysis of the implementation of a new guideline for colon cancer.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34149.
    PubMed     Abstract available


  24. ELMAHDI R, Wennerstrom ECM, Andersson M, Wohlfahrt J, et al
    Shared Environment and Colorectal Cancer: A Nordic Pedigree Registry-based Cohort Study.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34148.
    PubMed     Abstract available


    May 2022
  25. REINERT T, Petersen LMS, Henriksen TV, Larsen MO, et al
    Circulating tumor DNA for prognosis assessment and postoperative management after curative-intent resection of colorectal liver metastases.
    Int J Cancer. 2022;150:1537-1548.
    PubMed     Abstract available


    April 2022
  26. VAN DIJK E, van Werkhoven E, Asher R, Mooi JK, et al
    Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer; a post-hoc analysis of the randomized phase III-trial AGITG-MAX.
    Int J Cancer. 2022 Apr 30. doi: 10.1002/ijc.34061.
    PubMed     Abstract available


  27. LI M, Gong J, Bao Y, Huang D, et al
    Special issue "The advance of solid tumor research in China": Prognosis prediction for stage II colorectal cancer by fusing CT radiomics and deep-learning features of primary lesions and peripheral lymph nodes.
    Int J Cancer. 2022 Apr 29. doi: 10.1002/ijc.34053.
    PubMed     Abstract available


  28. CHEN LJ, Nguyen TNM, Chang-Claude J, Hoffmeister M, et al
    Incorporation of functional status, frailty, comorbidities, and co-medication in prediction models for colorectal cancer survival.
    Int J Cancer. 2022 Apr 18. doi: 10.1002/ijc.34036.
    PubMed     Abstract available


  29. BOTTERI E, Hoff G, Randel KR, Holme O, et al
    Characteristics of non-participants in a randomized colorectal cancer screening trial comparing sigmoidoscopy and faecal immunochemical testing.
    Int J Cancer. 2022 Apr 12. doi: 10.1002/ijc.34025.
    PubMed     Abstract available


    February 2022
  30. ORANGE ST, Jordan AR, Odell A, Kavanagh O, et al
    Acute aerobic exercise-conditioned serum reduces colon cancer cell proliferation through IL-6-induced regulation of DNA damage in vitro.
    Int J Cancer. 2022 Feb 25. doi: 10.1002/ijc.33982.
    PubMed     Abstract available


  31. OH CR, Kim JE, Hong YS, Kim SY, et al
    Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer.
    Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33966.
    PubMed     Abstract available


  32. IERACI L, Eberg M, Forster K, Murray PM, et al
    Development of population-level colon cancer pathway concordance measures and association with survival.
    Int J Cancer. 2022 Feb 16. doi: 10.1002/ijc.33964.
    PubMed     Abstract available


  33. GEBHARD C, Mulet-Lazaro R, Glatz D, Schwarzfischer-Pfeilschifter L, et al
    Aberrant DNA methylation patterns in microsatellite stable human colorectal cancers define a new marker panel for the CpG island methylator phenotype.
    Int J Cancer. 2022;150:617-625.
    PubMed     Abstract available


  34. MIAO Y, Xu Z, Feng W, Zheng M, et al
    Platelet infiltration predicts survival in postsurgical colorectal cancer patients.
    Int J Cancer. 2022;150:509-520.
    PubMed     Abstract available


    January 2022
  35. LUU XQ, Lee K, Jun JK, Suh M, et al
    Effect of colorectal cancer screening on long-term survival of colorectal cancer patients: Results of the Korea National Cancer Screening Program.
    Int J Cancer. 2022 Jan 31. doi: 10.1002/ijc.33953.
    PubMed     Abstract available


  36. AO T, Mochizuki S, Kajiwara Y, Yonemura K, et al
    Cancer-associated fibroblasts at the unfavorable desmoplastic stroma promote colorectal cancer aggressiveness: potential role of ADAM9.
    Int J Cancer. 2022 Jan 26. doi: 10.1002/ijc.33947.
    PubMed     Abstract available


  37. ZHOU X, Wang L, Xiao J, Sun J, et al
    Alcohol consumption, DNA methylation and colorectal cancer risk: Results from pooled cohort studies and Mendelian randomization analysis.
    Int J Cancer. 2022 Jan 25. doi: 10.1002/ijc.33945.
    PubMed     Abstract available


  38. JENNISKENS JCA, Offermans K, Simons CCJM, Samarska I, et al
    Energy balance-related factors in childhood and adolescence and risk of colorectal cancer expressing different levels of proteins involved in the Warburg-effect.
    Int J Cancer. 2022 Jan 22. doi: 10.1002/ijc.33941.
    PubMed     Abstract available


  39. TORTORA K, Margheri F, Luceri C, Mocali A, et al
    Colon fibroblasts from Pirc rats (F344/NTac-Apc(am1137) ) exhibit a proliferative and inflammatory phenotype that could support early stages of colon carcinogenesis.
    Int J Cancer. 2022;150:362-373.
    PubMed     Abstract available


  40. KEMPF E, Priou S, Lame G, Daniel C, et al
    Impact of two waves of Sars-Cov2 outbreak on the number, clinical presentation, care trajectories and survival of patients newly referred for a colorectal cancer: A French multicentric cohort study from a large group of University hospitals.
    Int J Cancer. 2022 Jan 9. doi: 10.1002/ijc.33928.
    PubMed     Abstract available


  41. YU YC, Paragomi P, Wang R, Jin A, et al
    Composite Dietary Antioxidant Index and the Risk of Colorectal Cancer: Findings from the Singapore Chinese Health Study.
    Int J Cancer. 2022 Jan 9. doi: 10.1002/ijc.33925.
    PubMed     Abstract available


    December 2021
  42. VANGALA DB, Ladigan-Badura S, Engel C, Huneburg R, et al
    Early detection of duodenal cancer by upper gastrointestinal-endoscopy in Lynch syndrome.
    Int J Cancer. 2021;149:2052-2062.
    PubMed     Abstract available


  43. HUANG Y, Hua X, Labadie JD, Harrison TA, et al
    Genetic variants associated with circulating C-reactive protein levels and colorectal cancer survival: Sex- and lifestyle factors- specific associations.
    Int J Cancer. 2021 Dec 9. doi: 10.1002/ijc.33897.
    PubMed     Abstract available


  44. HEISSER T, Hoffmeister M, Brenner H
    Model based evaluation of long-term efficacy of existing and alternative colorectal cancer screening offers: A case study for Germany.
    Int J Cancer. 2021 Dec 8. doi: 10.1002/ijc.33894.
    PubMed     Abstract available


  45. LUU HN, Tran MT, Nguyen MV, Tuong TT, et al
    Association between body mass index and colorectal adenomas: Findings from a case-control study in Vietnam.
    Int J Cancer. 2021;149:1898-1909.
    PubMed     Abstract available


  46. NIEDERMAIER T, Heisser T, Gies A, Guo F, et al
    To what extent is male excess risk of advanced colorectal neoplasms explained by known risk factors? Results from a large German screening population.
    Int J Cancer. 2021;149:1877-1886.
    PubMed     Abstract available


    November 2021
  47. MOEHLER M, Folprecht G, Heinemann V, Holch JW, et al
    Survival after secondary liver resection in metastatic colorectal cancer: Comparing data of three prospective randomized European trials (LICC, CELIM, FIRE-3).
    Int J Cancer. 2021 Nov 22. doi: 10.1002/ijc.33881.
    PubMed     Abstract available


    October 2021
  48. ZHU Y, Huang Y, Hu Y, Fang Y, et al
    Long-term Risk of Colorectal Cancer after Removal of Adenomas during Screening Colonoscopies in a Large Community-based Population in China.
    Int J Cancer. 2021 Oct 3. doi: 10.1002/ijc.33835.
    PubMed     Abstract available


    September 2021
  49. HUGEN N, Kanne H, Simmer F, van de Water C, et al
    Umbilical metastases: Real-world data shows abysmal outcome.
    Int J Cancer. 2021;149:1266-1273.
    PubMed     Abstract available


  50. MI N, Huang J, Huang C, Lin Y, et al
    High serum uric acid may associate with the increased risk of colorectal cancer in females: A prospective cohort study.
    Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33807.
    PubMed     Abstract available


  51. BOYLE JM, Kuryba A, Cowling TE, van der Meulen J, et al
    Survival outcomes associated with completion of adjuvant oxaliplatin-based chemotherapy for stage III colon cancer: a national population-based study.
    Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33806.
    PubMed     Abstract available


  52. LYNCH KT, Squeo GC, Kane WJ, Meneveau MO, et al
    A Pilot Trial of Vaccination with CEA and Her2 Peptides in Advanced Colorectal Cancer.
    Int J Cancer. 2021 Sep 3. doi: 10.1002/ijc.33793.
    PubMed     Abstract available


  53. BUCKSCH K, Zachariae S, Ahadova A, Aretz S, et al
    Adenoma and colorectal cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X.
    Int J Cancer. 2021 Sep 1. doi: 10.1002/ijc.33790.
    PubMed     Abstract available


    August 2021
  54. LANSDORP-VOGELAAR I, Meester R, de Jonge L, Buron A, et al
    Risk-stratified strategies in population screening for colorectal cancer.
    Int J Cancer. 2021 Aug 30. doi: 10.1002/ijc.33784.
    PubMed     Abstract available


  55. KOCH T, Therming Jorgensen J, Christensen J, Duun-Henriksen AK, et al
    Bilateral Oophorectomy and Rate of Colorectal Cancer: A Prospective Cohort Study.
    Int J Cancer. 2021 Aug 27. doi: 10.1002/ijc.33776.
    PubMed     Abstract available


  56. HE Y, Zhang X, Timofeeva M, Farrington SM, et al
    Bi-directional Mendelian randomisation analysis of the relationship between circulating vitamin D concentration and colorectal cancer risk.
    Int J Cancer. 2021 Aug 27. doi: 10.1002/ijc.33779.
    PubMed     Abstract available


  57. LIU L, Erickson NT, Ricard I, von Weikersthal LF, et al
    Early weight loss is an independent risk factor for shorter survival and increased side effects in patients with metastatic colorectal cancer undergoing first-line treatment within the randomized phase III trial FIRE-3 (AIO KRK-0306).
    Int J Cancer. 2021 Aug 25. doi: 10.1002/ijc.33775.
    PubMed     Abstract available


  58. ZHAO S, Chen L, Zang Y, Liu W, et al
    Endometrial cancer in lynch syndrome.
    Int J Cancer. 2021 Aug 16. doi: 10.1002/ijc.33763.
    PubMed     Abstract available


  59. MOCHIZUKI Y, Funayama R, Shirota M, Kikukawa Y, et al
    Alternative microexon splicing by RBFOX2 and PTBP1 is associated with metastasis in colorectal cancer.
    Int J Cancer. 2021 Aug 4. doi: 10.1002/ijc.33758.
    PubMed     Abstract available


    July 2021
  60. STAHLER A, Heinemann V, Holch JW, von Einem JC, et al
    Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3).
    Int J Cancer. 2021 Jul 26. doi: 10.1002/ijc.33747.
    PubMed     Abstract available


  61. VAN DER ZEE RP, Meijer CJLM, Cuming T, Kreuter A, et al
    Characterisation of anal intraepithelial neoplasia and anal cancer in HIV-positive men by immunohistochemical markers p16, Ki-67, HPV-E4, and DNA methylation markers.
    Int J Cancer. 2021 Jul 26. doi: 10.1002/ijc.33748.
    PubMed     Abstract available


  62. WATTS K, Wills C, Madi A, Palles C, et al
    Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
    Int J Cancer. 2021 Jul 16. doi: 10.1002/ijc.33739.
    PubMed     Abstract available


  63. KOSTOS L, Hong W, Lee B, Tran B, et al
    Cancer clinical trial vs real-world outcomes for standard of care first-line treatment in the advanced disease setting.
    Int J Cancer. 2021;149:409-419.
    PubMed     Abstract available


  64. NADEEM A, Aung KM, Ray T, Alam A, et al
    Suppression of beta-catenin signaling in colon carcinoma cells by a bacterial protein.
    Int J Cancer. 2021;149:442-459.
    PubMed     Abstract available


  65. CHENG CY, Datzmann T, Hernandez D, Schmitt J, et al
    Do certified cancer centers provide more cost-effective care? A health economic analysis of colon cancer care in Germany using administrative data.
    Int J Cancer. 2021 Jul 2. doi: 10.1002/ijc.33728.
    PubMed     Abstract available


  66. PAPADIMITRIOU N, Gunter MJ, Murphy N, Gicquiau A, et al
    Circulating tryptophan metabolites and risk of colon cancer: results from case-control and prospective cohort studies.
    Int J Cancer. 2021 Jul 1. doi: 10.1002/ijc.33725.
    PubMed     Abstract available


    June 2021
  67. GULLICKSON C, Goodman M, Joko-Fru YW, Gnangnon FHR, et al
    Colorectal cancer survival in sub-Saharan Africa by age, stage at diagnosis, and Human Development Index: A population-based registry study.
    Int J Cancer. 2021 Jun 24. doi: 10.1002/ijc.33715.
    PubMed     Abstract available


  68. CHAUDHARY N, Choudhary BS, Shah SG, Khapare N, et al
    Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer.
    Int J Cancer. 2021 Jun 19. doi: 10.1002/ijc.33711.
    PubMed     Abstract available


  69. MARCION G, Hermetet F, Neiers F, Uyanik B, et al
    Nanofitins targeting heat shock protein 110: An innovative immunotherapeutic modality in cancer.
    Int J Cancer. 2021;148:3019-3031.
    PubMed     Abstract available



  70. Retraction: DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-kB pathway in colorectal cancer. Weiying Liu, Shixing Wang, Qi Sun, Zhen Yang, Min Liu and Hua Tang. Int J Cancer. 2018 May 15;142(10):2068-2079.
    Int J Cancer. 2021 Jun 1. doi: 10.1002/ijc.33671.
    PubMed    


    May 2021
  71. ZORZI M, Battagello J, Fiore A, Memo L, et al
    Colorectal cancer incidence and mortality after negative fecal immunochemical tests by age 70: a prospective observational study.
    Int J Cancer. 2021 May 14. doi: 10.1002/ijc.33682.
    PubMed     Abstract available


  72. HAMFJORD J, Guren TK, Glimelius B, Sorbye H, et al
    Clinicopathological factors associated with tumour-specific mutation detection in plasma of patients with RAS- or BRAF-mutated metastatic colorectal cancer.
    Int J Cancer. 2021 May 7. doi: 10.1002/ijc.33672.
    PubMed     Abstract available


  73. SHAH R, Chan KKW
    The Impact of Socioeconomic Status on Stage at Presentation, Receipt of Diagnostic Imaging, Receipt of Treatment, and Overall Survival in Colorectal Cancer Patients.
    Int J Cancer. 2021 May 5. doi: 10.1002/ijc.33622.
    PubMed     Abstract available


  74. FANG Z, Hang D, Wang K, Joshi A, et al
    Risk prediction models for colorectal cancer: evaluating the discrimination due to added biomarkers.
    Int J Cancer. 2021 May 5. doi: 10.1002/ijc.33621.
    PubMed     Abstract available


  75. VAUGHAN-SHAW PG, Timofeeva M, Ooi LY, Svinti V, et al
    Differential genetic influences over colorectal cancer risk and gene expression in large bowel mucosa.
    Int J Cancer. 2021 May 2. doi: 10.1002/ijc.33616.
    PubMed     Abstract available


    April 2021
  76. AGLAGO EK, Murphy N, Huybrechts I, Nicolas G, et al
    Dietary intake and plasma phospholipid concentrations of saturated, monounsaturated and trans fatty acids and colorectal cancer risk in the EPIC cohort.
    Int J Cancer. 2021 Apr 28. doi: 10.1002/ijc.33615.
    PubMed     Abstract available


  77. LEE SH, Song IH, Jang HJ
    Feasibility of deep learning-based fully automated classification of microsatellite instability in tissue slides of colorectal cancer.
    Int J Cancer. 2021 Apr 13. doi: 10.1002/ijc.33599.
    PubMed     Abstract available


  78. WANG Y, Zhang Y, Qian Y, Xie YH, et al
    Alterations in the Oral and Gut Microbiome of Colorectal Cancer Patients and Association with Host Clinical Factors.
    Int J Cancer. 2021 Apr 12. doi: 10.1002/ijc.33596.
    PubMed     Abstract available


  79. DORIA-ROSE VP, Lansdorp-Vogelaar I, McCarthy S, Puricelli-Perin DM, et al
    Measures of longitudinal adherence to fecal-based colorectal cancer screening: literature review and recommended approaches.
    Int J Cancer. 2021 Apr 3. doi: 10.1002/ijc.33589.
    PubMed     Abstract available


  80. SHI Z, Wei J, Na R, Resurreccion WK, et al
    Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank.
    Int J Cancer. 2021;148:1658-1664.
    PubMed     Abstract available


  81. ZHU HB, Xu D, Ye M, Sun L, et al
    Deep learning-assisted magnetic resonance imaging prediction of tumor response to chemotherapy in patients with colorectal liver metastases.
    Int J Cancer. 2021;148:1717-1730.
    PubMed     Abstract available


  82. FLATIN BTB, Vedeld HM, Pinto R, Langerud J, et al
    Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability.
    Int J Cancer. 2021;148:1652-1657.
    PubMed     Abstract available


  83. APARICIO T, Svrcek M, Henriques J, Afchain P, et al
    Panel gene profiling of small bowel adenocarcinoma: Results from the NADEGE prospective cohort.
    Int J Cancer. 2021;148:1731-1742.
    PubMed     Abstract available


  84. DIMOU NL, Papadimitriou N, Mariosa D, Johansson M, et al
    Circulating adipokine concentrations and risk of five obesity-related cancers: A Mendelian randomization study.
    Int J Cancer. 2021;148:1625-1636.
    PubMed     Abstract available


    March 2021
  85. ZHOU J, Ge X, Fan X, Wang J, et al
    Associations of vitamin D status with colorectal cancer risk and survival.
    Int J Cancer. 2021 Mar 30. doi: 10.1002/ijc.33580.
    PubMed     Abstract available


  86. INDUKURI R, Jafferali MH, Song D, Damdimopoulos A, et al
    Genome-Wide Estrogen Receptor beta Chromatin Binding in Human Colon Cancer Cells Reveals its Tumor Suppressor Activity.
    Int J Cancer. 2021 Mar 22. doi: 10.1002/ijc.33573.
    PubMed     Abstract available


  87. HELGADOTTIR HT, Thutkawkorapin J, Rohlin A, Nordling M, et al
    Identification of known and novel familial cancer genes in Swedish colorectal cancer families.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33567.
    PubMed     Abstract available


  88. WEBSTER-CLARK M, Keil AP, Sanoff HK, Sturmer T, et al
    Introducing Longitudinal Cumulative Dose to Describe Chemotherapy Patterns Over Time: Case Study of a Colon Cancer Trial.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33565.
    PubMed     Abstract available


  89. QU X, Zhao L, Wang M, Zhang R, et al
    Novel functional variants in the Notch pathway and survival of Chinese colorectal cancer.
    Int J Cancer. 2021 Mar 17. doi: 10.1002/ijc.33561.
    PubMed     Abstract available


  90. VISCONTI P, Parodi F, Parodi B, Casarino L, et al
    Short tandem repeat profiling for the authentication of cancer stem-like cells.
    Int J Cancer. 2021;148:1489-1498.
    PubMed     Abstract available


  91. SHEN X, Shen X
    A potential role for aspirin in the prevention and treatment of cholangiocarcinoma.
    Int J Cancer. 2021;148:1323-1330.
    PubMed     Abstract available


    February 2021
  92. KIM H, Wang K, Song M, Giovannucci EL, et al
    A comparison of methods in estimating population attributable risk for colorectal cancer in the United States.
    Int J Cancer. 2021 Feb 2. doi: 10.1002/ijc.33489.
    PubMed     Abstract available


  93. HEIDRICH I, Ackar L, Mossahebi Mohammadi P, Pantel K, et al
    Liquid biopsies: Potential and challenges.
    Int J Cancer. 2021;148:528-545.
    PubMed     Abstract available


    January 2021
  94. MAKI-NEVALA S, Ukwattage S, Olkinuora A, Almusa H, et al
    Somatic mutation profiles as molecular classifiers of ulcerative colitis-associated colorectal cancer.
    Int J Cancer. 2021 Jan 31. doi: 10.1002/ijc.33492.
    PubMed     Abstract available


  95. JONGENEEL G, Greuter MJ, van Erning FN, Twisk JW, et al
    Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients: a prospective cohort study.
    Int J Cancer. 2021 Jan 18. doi: 10.1002/ijc.33472.
    PubMed     Abstract available


  96. DOMINGUEZ-VALENTIN M, Sampson JR, Moller P, Seppala TT, et al
    Analysis in the Prospective Lynch Syndrome Database identifies sarcoma as part of the Lynch syndrome tumor spectrum.
    Int J Cancer. 2021;148:512-513.
    PubMed    


  97. HE Y, Timofeeva M, Zhang X, Xu W, et al
    Colorectal cancer risk variants rs10161980 and rs7495132 are associated with cancer survival outcome by a recessive mode of inheritance.
    Int J Cancer. 2021 Jan 7. doi: 10.1002/ijc.33465.
    PubMed     Abstract available


  98. WANG L, Hang D, He X, Lo CH, et al
    A prospective study of erythrocyte polyunsaturated fatty acids and risk of colorectal serrated polyps and conventional adenomas.
    Int J Cancer. 2021;148:57-66.
    PubMed     Abstract available


    December 2020
  99. LONG L, Yang W, Liu L, Tobias DK, et al
    Dietary intake of branched-chain amino acids and survival after colorectal cancer diagnosis.
    Int J Cancer. 2020 Dec 19. doi: 10.1002/ijc.33449.
    PubMed     Abstract available


  100. JENSEN BV, Schou JV, Yilmaz M, Johannesen HH, et al
    Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status.
    Int J Cancer. 2020 Dec 17. doi: 10.1002/ijc.33448.
    PubMed     Abstract available


  101. HEISSER T, Hoffmeister M, Brenner H
    Effects of Screening for Colorectal Cancer: Development, Documentation and Validation of a Multistate Markov Model.
    Int J Cancer. 2020 Dec 15. doi: 10.1002/ijc.33437.
    PubMed     Abstract available


  102. ORNTOFT MW, Jensen SO, Ogaard N, Henriksen TV, et al
    Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
    Int J Cancer. 2020 Dec 15. doi: 10.1002/ijc.33434.
    PubMed     Abstract available


  103. INNOMINATO PF, Karaboue A, Focan C, Chollet P, et al
    Efficacy and safety of chronomodulated Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the international EORTC 05011 trial.
    Int J Cancer. 2020 Dec 3. doi: 10.1002/ijc.33422.
    PubMed     Abstract available


    November 2020
  104. BLAKER H, Haupt S, Morak M, Holinski-Feder E, et al
    Age-dependent performance of BRAF mutation testing in Lynch syndrome diagnostics.
    Int J Cancer. 2020;147:2801-2810.
    PubMed     Abstract available


  105. ZHAN T, Faehling V, Rauscher B, Betge J, et al
    Multi-omics integration identifies a selective vulnerability of colorectal cancer subtypes to YM155.
    Int J Cancer. 2020 Nov 13. doi: 10.1002/ijc.33393.
    PubMed    


    October 2020
  106. REINHOLDT K, Thomsen LT, Munk C, Dehlendorff C, et al
    Incidence of HPV-related anogenital precancer and cancer in women with diabetes - a nationwide registry-based cohort study.
    Int J Cancer. 2020 Oct 31. doi: 10.1002/ijc.33365.
    PubMed     Abstract available


  107. THURMAIER J, Heinemann V, Engel J, Schubert-Fritschle G, et al
    Patients with colorectal cancer and brain metastasis: The relevance of extracranial metastatic patterns predicting time intervals to first occurrence of intracranial metastasis and survival.
    Int J Cancer. 2020 Oct 28. doi: 10.1002/ijc.33364.
    PubMed     Abstract available


  108. HE MM, Fang Z, Hang D, Wang F, et al
    Circulating Liver Function Markers and Colorectal Cancer Risk: A Prospective Cohort Study in the UK Biobank.
    Int J Cancer. 2020 Oct 22. doi: 10.1002/ijc.33351.
    PubMed     Abstract available


  109. LI L, Duan Q, Zeng Z, Zhao J, et al
    UHRF2 promotes intestinal tumorigenesis through stabilization of TCF4 mediated Wnt/beta-catenin signaling.
    Int J Cancer. 2020;147:2239-2252.
    PubMed     Abstract available


  110. LANG M, Baumgartner M, Rozalska A, Frick A, et al
    Crypt residing bacteria and proximal colonic carcinogenesis in a mouse model of Lynch syndrome.
    Int J Cancer. 2020;147:2316-2326.
    PubMed     Abstract available


  111. SCHLICKER A, Ellappalayam A, Beumer IJ, Snel MHJ, et al
    Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis.
    Int J Cancer. 2020;147:2303-2315.
    PubMed     Abstract available


  112. GERMANOVA D, Keirsse J, Kohler A, Hastir JF, et al
    Myeloid TNF and HO-1 regulate the progression of colorectal liver metastases during hepatic ischemia-reperfusion.
    Int J Cancer. 2020 Oct 10. doi: 10.1002/ijc.33334.
    PubMed     Abstract available


  113. PILLERON S, Charvat H, Araghi M, Arnold M, et al
    Age disparities in stage-specific colon cancer survival across seven countries: an ICBP SURVMARK-2 population-based study.
    Int J Cancer. 2020 Oct 2. doi: 10.1002/ijc.33326.
    PubMed     Abstract available


  114. JARY M, Hasanova R, Vienot A, Asgarov K, et al
    Molecular description of ANGPT2 associated colorectal carcinoma.
    Int J Cancer. 2020;147:2007-2018.
    PubMed     Abstract available


    September 2020
  115. TIE J, Cohen JD, Lo SN, Wang Y, et al
    Prognostic Significance of Post-Surgery Circulating Tumor DNA in Non-Metastatic Colorectal Cancer: Individual Patient Pooled Analysis of Three Cohort Studies.
    Int J Cancer. 2020 Sep 27. doi: 10.1002/ijc.33312.
    PubMed     Abstract available


  116. UNSELD M, Belic J, Pierer K, Zhou Q, et al
    A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy (RELAIS) translational biomarker phase II pilot study.
    Int J Cancer. 2020 Sep 19. doi: 10.1002/ijc.33303.
    PubMed     Abstract available


  117. LADIGAN-BADURA S, Vangala DB, Engel C, Bucksch K, et al
    Value of upper GI endoscopy for gastric cancer surveillance in patients with Lynch syndrome.
    Int J Cancer. 2020 Sep 15. doi: 10.1002/ijc.33294.
    PubMed     Abstract available


  118. JANAKIRAMAN H, Zhu Y, Becker SA, Wang C, et al
    Modeling rectal cancer to advance neoadjuvant precision therapy.
    Int J Cancer. 2020;147:1405-1418.
    PubMed     Abstract available


    August 2020
  119. ACHILLI P, Crippa J, Grass F, Larson DW, et al
    Reply to: Comments on "Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database".
    Int J Cancer. 2020 Aug 15. doi: 10.1002/ijc.33256.
    PubMed    


  120. DIZDAR O
    Comments on "Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database".
    Int J Cancer. 2020 Aug 15. doi: 10.1002/ijc.33258.
    PubMed    


  121. LOOPIK DL, Ebisch RM, IntHout J, Melchers WJ, et al
    The relative risk of noncervical high-risk human papillomavirus-related (pre)malignancies after recurrent cervical intraepithelial neoplasia grade 3: A population-based study.
    Int J Cancer. 2020;147:897-900.
    PubMed     Abstract available


  122. WALPOLE E, Dunn N, Youl P, Harden H, et al
    Nonbreast cancer incidence, treatment received and outcomes: Are there differences in breast screening attendees versus nonattendees?
    Int J Cancer. 2020;147:856-865.
    PubMed     Abstract available


  123. TAO W, Artama M, von Euler-Chelpin M, Hull M, et al
    Colon and rectal cancer risk after bariatric surgery in a multicountry Nordic cohort study.
    Int J Cancer. 2020;147:728-735.
    PubMed     Abstract available


  124. CARIOLI G, Bertuccio P, Malvezzi M, Rodriguez T, et al
    Cancer mortality predictions for 2019 in Latin America.
    Int J Cancer. 2020;147:619-632.
    PubMed     Abstract available


    July 2020
  125. FELGNER S, Sporing I, Pawar V, Kocijancic D, et al
    The immunogenic potential of bacterial flagella for Salmonella-mediated tumor therapy.
    Int J Cancer. 2020;147:448-460.
    PubMed     Abstract available


  126. CLIFFORD GM, Georges D, Shiels MS, Engels EA, et al
    A meta-analysis of anal cancer incidence by risk group: towards a unified anal cancer risk scale.
    Int J Cancer. 2020 Jul 4. doi: 10.1002/ijc.33185.
    PubMed     Abstract available


  127. PONTI A, Basu P, Ritchie D, Anttila A, et al
    Key issues that need to be considered while revising the current annex of the European Council Recommendation (2003) on cancer screening.
    Int J Cancer. 2020;147:9-13.
    PubMed     Abstract available


    May 2020
  128. HWANG JH, Yoon J, Cho YH, Cha PH, et al
    A mutant KRAS-induced factor REG4 promotes cancer stem cell properties via Wnt/beta-catenin signaling.
    Int J Cancer. 2020;146:2877-2890.
    PubMed     Abstract available


    November 2019
  129. NOH H, Charvat H, Freisling H, Olafsdottir GH, et al
    Cumulative exposure to premenopausal obesity and risk of postmenopausal cancer: A population-based study in Icelandic women.
    Int J Cancer. 2019 Nov 21. doi: 10.1002/ijc.32805.
    PubMed     Abstract available


  130. COMBES JD, Clifford GM, Gunthard HF, Hauser C, et al
    Antibodies against HPV16E6 oncoprotein in the Swiss HIV Cohort Study: kinetics and anal cancer risk prediction.
    Int J Cancer. 2019 Nov 12. doi: 10.1002/ijc.32784.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: